Загрузка...
73 Changes in Palivizumab usage in Canada 2005–2017 (Data from CARESS registry)
BACKGROUND: Palivizumabis a monoclonal antibody for preventionof serious lower respiratory tract infection caused by respiratory syncytial virus (RSV) in high risk children. Safety and efficacy were established in infants with bronchopulmonary dysplasia (BPD), prematurity (≤ 35 weeks gestational age...
Сохранить в:
| Опубликовано в: : | Paediatr Child Health |
|---|---|
| Главные авторы: | , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Oxford University Press
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6543311/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/pch/pxz066.072 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|